Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 464,825 shares, a growth of 82.1% from the August 31st total of 255,272 shares. Approximately 3.4% of the shares of the company are short sold. Based on an average daily trading volume, of 1,042,222 shares, the days-to-cover ratio is currently 0.4 days.

Biofrontera Price Performance

NASDAQ BFRI traded down $0.01 during trading hours on Wednesday, reaching $1.08. 272,746 shares of the company’s stock were exchanged, compared to its average volume of 419,667. The firm has a fifty day moving average of $1.32 and a 200-day moving average of $1.10. Biofrontera has a one year low of $0.55 and a one year high of $1.66. The stock has a market cap of $16.04 million, a PE ratio of -2.40 and a beta of 0.83. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.78.

Biofrontera (NASDAQ:BFRI) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. Biofrontera had a negative return on equity of 145.81% and a negative net margin of 13.78%.The company had revenue of $12.00 million for the quarter, compared to analyst estimates of $9.50 million. On average, equities research analysts predict that Biofrontera will post -0.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

BFRI has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Zacks Research upgraded Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Wall Street Zen cut Biofrontera from a “buy” rating to a “hold” rating in a report on Sunday, September 20th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

About Biofrontera

Biofrontera Inc (NASDAQ:BFRI) is a commercial-stage biopharmaceutical company focused on dermatology. The company develops and markets prescription therapies for the treatment of skin conditions, with an emphasis on products that address actinic keratosis and other dermatologic diseases.

Its principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, which is used in combination with the BF-RhodoLED lamp in photodynamic therapy for actinic keratoses. Biofrontera also provides the BF-RhodoLED photodynamic therapy lamp system used by healthcare professionals to activate the treatment.

Biofrontera Inc is based in the United States and operates as part of the broader Biofrontera corporate group, which has German roots and an international dermatology business.